Karen A. Gelmon

2775 Laurel Street
Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 247 publications

The UVA-induced single-base mutational signature of CX-5461 in human cells.

The UVA-induced single-base mutational signature of CX-5461 in human cells.

Journal: Nucleic acids research

Published: April 17, 2026

International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study.

International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study.

Journal: Breast (Edinburgh, Scotland)

Published: February 27, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.

Journal: Breast cancer research and treatment

Published: February 18, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Journal: Current oncology (Toronto, Ont.)

Published: January 28, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Journal: Current oncology (Toronto, Ont.)

Published: January 16, 2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Journal: Current oncology (Toronto, Ont.)

Published: December 24, 2025

Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.

Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.

Journal: JNCI cancer spectrum

Published: December 17, 2025

Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the United States and Canada.

Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the United States and Canada.

Journal: Oncology and therapy

Published: December 16, 2025

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

Journal: Current oncology (Toronto, Ont.)

Published: December 07, 2025

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32.

Journal: JNCI cancer spectrum

Published: November 17, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Showing 1-12 of 247

Last Updated: 09/26/2026